Drug General Information (ID: DDIONM7Y5L)
Drug Name			Urokinase		Drug Info		Collagenase clostridium histolyticum		Drug Info
Drug Type		Protein/peptide				Protein/peptide
Therapeutic Class		Thrombolytics				Collagenase Enzyme

Mechanism of Urokinase-Collagenase clostridium histolyticum Interaction (Severity Level: Moderate)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Urokinase				Collagenase clostridium histolyticum
Mechanism		Risk of bleeding Thrombolytic agent				Risk of bleeding Antiplatelet/anticoagulant effects
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Urokinase and Collagenase clostridium histolyticum

Recommended Action
Management		Collagenase clostridium histolyticum should be used with caution in patients receiving or within 7 days of receiving anticoagulants (except for low-dose aspirin), platelet inhibitors, or thrombolytic agents.

References
1	Product Information. Xiaflex (collagenase clostridium histolyticum). Auxilium Pharmaceuticals Inc, Norristown, PA.